A retrospective study from the European Group for Blood and Marrow Transplantation showed increased incidence of grades II–IV acute GVHD and chronic GVHD with G‐CSF administration among BMT patients, but not PBSCT patients.7 The gene discussed is CSF3; the disease is chronic graft versus host disease.